Clinical Trial Update: A Study of Niraparib as Maintenance Therapy Following First-Line Platinum-Based Chemotherapy in Patients With Extensive Stage Small Cell Lung Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating niraparib as maintenance therapy after first-line platinum chemotherapy in extensive-stage small cell lung cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extensive-stage Small Cell Lung Cancer

Drugs mentioned

• Niraparib (Niraparib)

Snippet

Sponsor: Zai Lab (Shanghai) Co., Ltd. | Conditions: Extensive-stage Small Cell Lung Cancer | Phase 3 | Status: TERMINATED